NDA 50648, held by Baxter Hlthcare. Clindamycin Phosphate.
As of Nov 13, 2026, NDA 50648 (Clindamycin Phosphate In Dextrose 5% In Plastic Container), held by Baxter Hlthcare, was first approved by FDA on Dec 29, 1989, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 29, 1989 | Original applicationNew dosage form · Standard review | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clindamycin Phosphate In Dextrose 5% In Plastic ContainerEQ 6MG BASE/ML · injectable;injection | Clindamycin Phosphate | Discontinued |
| Clindamycin Phosphate In Dextrose 5% In Plastic ContainerEQ 12MG BASE/ML · injectable;injection | Clindamycin Phosphate | Discontinued |
| Clindamycin Phosphate In Dextrose 5% In Plastic ContainerEQ 900MG BASE/100ML · injectable;injection | Clindamycin Phosphate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
